Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice

Clinical Immunology

Volumn 151, Issue 2, 2014, Pages 155-163

  Ulusoy, Canan ^a   Kim, Eunmi ^b   Tüzün, Erdem ^a   Huda, Ruksana ^b   Yilmaz, Vuslat ^c   Poulas, Konstantinos ^d   Trakas, Nikos ^e   Skriapa, Lamprini ^d,e   Niarchos, Athanasios ^d   Strait, Richard T ^f   Finkelman, Fred D ^f,g,h   Turan, Selin ^a   Zisimopoulou, Paraskevi ^e   Tzartos, Socrates ^d,e   Saruhan Direskeneli, Güher ^c   Christadoss, Premkumar ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b University of Texas Medical Branch School of Medicine   (United States)

^c ISTANBUL UNIVERSITY   (Turkey)

^d UNIVERSITY OF PATRAS   (Greece)

^e HELLENIC PASTEUR INSTITUTE   (Greece)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Anti MuSK IgG1; Experimental autoimmune myasthenia gravis; IL 10; IL 4; Muscle specific kinase; Myasthenia gravis

Indexed keywords

FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MUSCLE SPECIFIC RECEPTOR KINASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE PREDISPOSITION; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; GRIP STRENGTH; IMMUNOGLOBULIN PRODUCTION; LYMPH NODE CELL; MOUSE; MUSCLE WEAKNESS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH2 CELL;

ANTI-MUSK IGG1; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; IL-10; IL-4; MUSCLE SPECIFIC KINASE; MYASTHENIA GRAVIS;

ANIMALS; ANTIBODY SPECIFICITY; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; IMMUNIZATION; IMMUNOGLOBULIN G; INTERLEUKIN-10; INTERLEUKIN-4; LYMPH NODES; MICE; MICE, KNOCKOUT; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84896056386     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.02.012     Document Type: Article

References (27)

1. Vincent A., Drachman D.B. Myasthenia gravis. Adv. Neurol. 2002, 88:159-188.
2. Drachman D.B., Angus C.W., Adams R.N., Michelson J.D., Hoffman G.J. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N. Engl. J. Med. 1978, 298:1116-1122.
3. Cossins J., Belaya K., Zoltowska K., Koneczny I., Maxwell S., Jacobson L., et al. The search for new antigenic targets in myasthenia gravis. Ann. N. Y. Acad. Sci. 2012, 1275:123-128.
4. Klooster R., Plomp J.J., Huijbers M.G., Niks E.H., Straasheijm K.R., Detmers F.J., Hermans P.W., Sleijpen K., Verrips A., Losen M., Martinez-Martinez P., De Baets M.H., van der Maarel S.M., Verschuuren J.J. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 2012, 135:1081-1101.
5. Richman D.P., Nishi K., Ferns M.J., Schnier J., Pytel P., Maselli R.A., Agius M.A. Animal models of antimuscle-specific kinase myasthenia. Ann. N. Y. Acad. Sci. 2012, 1274:140-147.
6. Niks E.H., van Leeuwen Y., Leite M.I., Dekker F.W., Wintzen A.R., Wirtz P.W., Vincent A., van Tol M.J., Jol-van der Zijde C.M., Verschuuren J.J. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J. Neuroimmunol. 2008, 195:151-156.
7. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., Beeson D., Willcox N., Vincent A. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
8. Mori S., Yamada S., Kubo S., Chen J., Matsuda S., Shudou M., Maruyama N., Shigemoto K. Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis. J. Neuroimmunol. 2012, 244:1-7.
9. Shiraishi H., Motomura M., Yoshimura T., Fukudome T., Fukuda T., Nakao Y., Tsujihata M., Vincent A., Eguchi K. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann. Neurol. 2005, 57:289-293.
10. Tüzün E., Huda R., Christadoss P. Complement and cytokine based therapeutic strategies in myasthenia gravis. J. Autoimmun. 2011, 37:136-143.
11. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 2004, 172:2731-2738.
12. van de Veen W., Stanic B., Yaman G., Wawrzyniak M., Söllner S., Akdis D.G., Rückert B., Akdis C.A., Akdis M. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J. Allergy Clin. Immunol. 2013, 131:1204-1212.
13. Silva A.S., Cavalcante L.T., Faquim-Mauro E.L., Macedo M.S. Regulation of anaphylactic IgG1 antibody production by IL-4 and IL-10. Int. Arch. Allergy Immunol. 2006, 141:70-78.
14. Jung S., Rajewsky K., Radbruch A. Shutdown of class switch recombination by deletion of a switch region control element. Science 1993, 259:984-987.
15. Trakas N., Zisimopoulou P., Tzartos S.J. Development of a highly sensitive diagnostic assay for muscle-specific tyrosine kinase (MuSK) autoantibodies in myasthenia gravis. J. Neuroimmunol. 2011, 240-241:79-86.
16. Psaridi-Linardaki L., Mamalaki A., Remoundos M., Tzartos S.J. Expression of soluble ligand- and antibody-binding extracellular domain of human muscle acetylcholine receptor alpha subunit in yeast Pichia pastoris. Role of glycosylation in alpha-bungarotoxin binding. J. Biol. Chem. 2002, 277:26980-26986.
17. Wu B., Goluszko E., Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Curr. Protoc. Immunol. May 2001, 15.8:1-26.
18. Christadoss P., Poussin M., Deng C. Animal models of myasthenia gravis. Clin. Immunol. 2000, 94:75-87.
19. Mori S., Kubo S., Akiyoshi T., Yamada S., Miyazaki T., Hotta H., Desaki J., Kishi M., Konishi T., Nishino Y., Miyazawa A., Maruyama N., Shigemoto K. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am. J. Pathol. 2012, 180:798-810.
20. Klein-Schneegans A.S., Kuntz L., Fonteneau P., Loor F. Serum concentrations of IgM, IgG1, IgG2b, IgG3 and IgA in C57BL/6 mice and their congenics at the lpr (lymphoproliferation) locus. J. Autoimmun. 1989, 2:869-875.
21. Deng C., Goluszko E., Tüzün E., Yang H., Christadoss P. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. 2002, 169:1077-1083.
22. Tüzün E., Scott B.G., Goluszko E., Higgs S., Christadoss P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J. Immunol. 2003, 171:3847-3854.
23. Scott M.G., Briles D.E., Nahm M.H. Selective IgG subclass expression: biologic, clinical and functional aspects. The Human IgG Subclasses: Molecular Analysis of Structure and Function 1990, 161-183. Pergamon Press, Oxford. F. Shakib (Ed.).
24. Strait R., Mahler A., Barasa N., Stringer K., Witte D., Herr A., Finkelman F. IgG1 protects against IgG3 immune complex mediated renal disease. J. Immunol. 2012, 188(Suppl. 1):176.21. (Abstract).
25. Stevens T.L., Bossie A., Sanders V.M., Fernandez-Botran R., Coffman R.L., Mosmann T.R., Vitetta E.S. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988, 334:255-258.
26. Rødgaard A., Nielsen F.C., Djurup R., Somnier F., Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin. Exp. Immunol. 1987, 67:82-88.
27. Cribbs D.H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., Babikyan D., Kesslak P., Kieber-Emmons T., Cotman C.W., Agadjanyan M.G. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 2003, 15:505-514.